Yueying Liu1, Hong Ni2, Chunhong Wang1, Lili Li2, Zaohuo Cheng3, Zhen Weng4. 1. 1 Department of Pediatrics, Affiliated Hospital, Jiangnan University , Wuxi, Jiangsu, China . 2. 2 Neurology Laboratory, Soochow University Affiliated Children's Hospital , Suzhou, Jiangsu, China . 3. 3 Department of Clinical Psychology, Wuxi Mental Health Center affiliated to Nanjing Medical University , Wuxi, Jiangsu, China . 4. 4 Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics , Chinese Academy of Sciences, Suzhou, Jiangsu, China .
Abstract
OBJECTIVE: Aripiprazole, an atypical antipsychotic drug, has shown potential as a promising candidate for the treatment of Tourette's disorder (TD). However, the effectiveness and the tolerability profile of aripiprazole in the reduction of tics in children and adolescents with TD have not been systematically analyzed. This meta-analysis aimed to evaluate the effectiveness and tolerability of aripiprazole in children and adolescents with TD. METHODS: We searched for clinical trials that investigated the effect of aripiprazole in children and adolescents with TD in PubMed and Web of Science. The outcomes of interest comprised the Yale Global Tic Severity Score (YGTSS) total tic scores and the Clinical Global Impressions Scale for Tic Severity (CGI-S) scores. The pooled effect size (ES) and 95% confidence interval (CI) were calculated to assess the effectiveness of aripiprazole in children and adolescents with TD. RESULTS: Ten studies were retrieved from 122 citations for the analysis, and in total, 302 patients (mean age, 11.6 years; median follow-up, 9 weeks) were included in the analysis. After synthesis of the data, the meta-analysis showed significantly greater improvement in the mean change in the YGTSS total tic scores (ES = -1.99, 95% CI = [-2.26]-[-1.72]; p = 0.001) and the mean CGI-S scores (ES = -2.34, 95% CI = [-2.96]-[-1.73]; p = 0.001) from pretreatment to posttreatment. Adverse events were reported in nine trials. Drowsiness (28.5%), nausea (20.2%), and headache (13.8%) were common adverse events. CONCLUSIONS: The use of aripiprazole is safe, and shows therapeutic effectiveness in children and adolescents with TD.
OBJECTIVE:Aripiprazole, an atypical antipsychotic drug, has shown potential as a promising candidate for the treatment of Tourette's disorder (TD). However, the effectiveness and the tolerability profile of aripiprazole in the reduction of tics in children and adolescents with TD have not been systematically analyzed. This meta-analysis aimed to evaluate the effectiveness and tolerability of aripiprazole in children and adolescents with TD. METHODS: We searched for clinical trials that investigated the effect of aripiprazole in children and adolescents with TD in PubMed and Web of Science. The outcomes of interest comprised the Yale Global Tic Severity Score (YGTSS) total tic scores and the Clinical Global Impressions Scale for Tic Severity (CGI-S) scores. The pooled effect size (ES) and 95% confidence interval (CI) were calculated to assess the effectiveness of aripiprazole in children and adolescents with TD. RESULTS: Ten studies were retrieved from 122 citations for the analysis, and in total, 302 patients (mean age, 11.6 years; median follow-up, 9 weeks) were included in the analysis. After synthesis of the data, the meta-analysis showed significantly greater improvement in the mean change in the YGTSS total tic scores (ES = -1.99, 95% CI = [-2.26]-[-1.72]; p = 0.001) and the mean CGI-S scores (ES = -2.34, 95% CI = [-2.96]-[-1.73]; p = 0.001) from pretreatment to posttreatment. Adverse events were reported in nine trials. Drowsiness (28.5%), nausea (20.2%), and headache (13.8%) were common adverse events. CONCLUSIONS: The use of aripiprazole is safe, and shows therapeutic effectiveness in children and adolescents with TD.